Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03779061 | Study of Remimazolam Tosilate in Patients Undergoing Colonoscopy | PHASE3 | COMPLETED | 388 | — | — | Jun 28, 2018 | Sep 28, 2018 | Dec 19, 2018 | 1 | China |
successful sedation rate as measured by the proportion of subjects who experienced successful sedation during colonoscopy
| Arm | Type | Description |
|---|---|---|
| Remimazolam Tosilate | EXPERIMENTAL | - |
| Propofol | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Remimazolam Tosilate | DRUG | Initial dose plus supplemental doses as necessary |
| Propofol | DRUG | Initial dose plus supplemental doses as necessary |
Inclusion Criteria: * subjects aged 18-65 years； * intending to undergo colonoscopy; * ASA( American Society of Anesthesiologists) I or II； * 18 kg/m²\<BMI(Body Mass Index)\<30 kg/m²; * the operation time of gastroscopy is not more than 30 min； * Signed informed consent. Exclusion Criteria: Patie...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Masimo Corporation | MASI | 1 | PHASE1 | Diprivan , Astra-Zeneca |
| Cardinal Health, Inc. | CAH | 1 | — | Undisclosed |
| Medtronic Plc | MDT | 1 | NA | Undisclosed |